Download PDF
TumorDiagnostik & Therapie 2019; 40(10): 653-657
DOI: 10.1055/a-0961-9765
Schwerpunkt Zell- und Gentherapie
© Georg Thieme Verlag KG Stuttgart · New York

CAR-T-Zell-Therapie hämatologischer Tumoren

Hinrich Abken
Further Information

Publication History

Publication Date:
29 November 2019 (online)

Also available at
    Permissions and Reprints

Die adoptive Zell-Therapie mit chimären Antigenrezeptor (CAR)-modifizierten T-Zellen hat die Behandlungsmöglichkeiten hämatologischer Tumoren in den letzten Jahren wesentlich erweitert. Für Patienten mit refraktärer Erkrankung oder mit Rezidiv, die bisher nur wenige Behandlungsoptionen hatten, induzierte die CAR-T-Zell-Therapie beeindruckende Ansprechraten.
 

  • Literatur

  • 1 Maude SL, Laetsch TW, Buechner J. et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-448
    CrossrefPubMedGoogle Scholar
  • 2 Schuster SJ, Bishop M, Tam C. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. N Engl J Med 2019; 380: 45-56
    CrossrefPubMedGoogle Scholar
  • 3 Locke F, Ghobadi A, Jacobson CA. et al. Long‐term safety and activity of axicabtagene ciloleucel in refractory large B‐cell lymphoma (ZUMA‐1): a single‐arm, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 31-42
    CrossrefPubMedGoogle Scholar
  • 4 Abramson J, Gordon L, Palomba ML. et al. Updated safety and long‐term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol 2018; 36 (15) 7505
    CrossrefPubMedGoogle Scholar
  • 5 Park JH, Palomba ML, Batlevi C. et al. A phase I first‐in‐human clinical trial of CD19‐targeted 19‐28z/4‐1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including Richter’s transformation. Blood 2018; 132: 224
    CrossrefPubMedGoogle Scholar
  • 6 Fry TJ, Shah NN, Orentas RJ. et al. CD22‐targeted CAR T cells induce remission in B‐ALL that is naïve or resistant to CD19‐targeted CAR immunotherapy. Nat Med 2018; 24: 20-28
    CrossrefPubMedGoogle Scholar
  • 7 Mailankody S, Ghosh A, Staehr M. et al. Clinical responses and pharmocokinetics of MCARH171, a human‐derived bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I clinical trial. Blood 2018; 132: 959
    CrossrefPubMedGoogle Scholar
  • 8 Chmielewski M, Abken H. TRUCKs: the new generation of CARs. Expert Opinion Biol Ther 2015; 15: 1145-1154
    PubMedGoogle Scholar
  • 9 Porter DL, Hwang WT, Frey NV. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139
    CrossrefPubMedGoogle Scholar
  • 10 Kochenderfer JN, Somerville RPT, Lu T. et al. Lymphoma remissions caused by anti‐CD19 chimeric antigen receptor T cells are associated with high serum interleukin‐15 levels. J Clin Oncol 2017; 35: 1803-1813
    CrossrefPubMedGoogle Scholar
  • 11 Turtle CJ, Hay KA, Hanafi LA. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19‐specific chimeric antigen receptor‐modified T cells after failure of ibrutinib. J Clin Oncol 2017; 35: 3010-3020
    CrossrefPubMedGoogle Scholar
  • 12 Schuster SJ, Svoboda J, Chong EA. et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 2017; 377: 2545-2554
    CrossrefPubMedGoogle Scholar
  • 13 Park JH, Riviere I, Gonen M. et al. Long‐term follow‐up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018; 378: 449-459
    CrossrefPubMedGoogle Scholar
  • 14 Svoboda J, Rheingold SR, Gill SI. et al. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood 2018; 132: 1022-1026
    PubMedGoogle Scholar